PIPELINE
THE BENEFITS
THE BENEFITS
OF OUR PAYLOAD
Merlin is developing novel approaches to diseases where there are few effective therapies. Our lead asset, MER-101 is a first-in-class immuno-oncology therapy being developed solely by Merlin for adult solid cancers and pediatric sarcomas.
![](https://www.merlinbiotech.com/wp-content/uploads/2023/01/img-hero-09@2x-750x750.webp)